Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Kennedy Institute for Rheumatology and the Institute of Developmental and Regenerative Medicine announce the launch of the Oxford-Zeiss Centre of Excellence, providing state-of-the-art imaging technologies to lead future discoveries in global health and disease.

Confocal imaging of antigen-induced arthritis in mouse knee. Image taken by Kristina Zec
Confocal imaging of antigen-induced arthritis in mouse knee. Image taken by Kristina Zec.

A new Oxford-Zeiss Centre of Excellence (Oxford-ZCoE) in Biomedical Imaging has opened its doors to researchers at the University of Oxford. A strategic partnership between the Kennedy Institute of Rheumatology (KIR) and the Institute of Developmental and Regenerative Medicine (IDRM), the new centre brings advanced state-of-the-art Zeiss imaging equipment and analysis tools to advance the study of global health and disease.

The first centre of its kind in the UK and Europe, Oxford-ZCoE is centred on the close relationship between the Carl Zeiss AG and Oxford. Professor Marco Fritzsche, Scientific Director of the Oxford-ZCoE said: "Our partnership with Zeiss has enabled Oxford to develop a facility providing the latest technologies in live imaging that will keep it competitive with international research."

The KIR and IRDM have broad research interests across immunology, neurology, embryology, cardiology, and cancer. Their goal is to study the key biological processes that underpin normal healthy development, and where these may go wrong in disease. Improvements in microscopy resolution and fast imaging enable researchers to observe complex functions and behaviour at the single cell level, within tissues, and across whole organisms. The Oxford-ZCoE provides a broad spectrum of different technologies that can answer research questions in living samples with a view to treating some of the world's most prolific diseases such as cancer, cardiovascular disease, neuro-degenerative diseases, or conditions related to inflammation or tissue repair.

For example, in addition to a range of recently installed lattice light sheet microscopes, the centre has introduced two of the latest fast Zeiss 980 Airyscan confocals. These state-of-the-art microscopes are the workhorses of super-resolution imaging and include super-fast scanners and spectroscopy. These sit alongside a multi-photon microscope for powerful deep imaging, and low magnification systems for imaging fixed tissues and large tile regions. All the microscopy technologies are supported by arivis AG (a Zeiss company), who provide the software for image analysis and interpretation, ensuring researchers have a complete end-to-end service.

One of the most future thinking aspects of the partnership with Zeiss is its ability to evolve the imaging facility based on the latest research questions.

"We have built a concept that not only gives our researchers access to the latest commercially available optical imaging microscopes, but also to the unique expertise of Zeiss engineers in their Research and Development team," explained Professor Fritzsche. "This gives us the freedom to raise questions relating to our areas of biological study that may challenge current microscopy capabilities, allowing us to continue to develop new technologies and transform microscopy across our research interests."

"ZEISS are delighted to have formed such an important strategic partnership with the KIR at the University of Oxford in the year of our 175th anniversary. Close collaboration with great scientific minds has been at the forefront of ZEISS' philosophy from the inception of the company in 1846 and continues to this day," said aid Dr. Ben Ewins, ZEISS account manager for Oxford University.

Read the full story on the NDORMS website. 

Similar stories

New research reveals relationship between particular brain circuits and different aspects of mental wellbeing

Researchers at the University of Oxford have uncovered previously unknown details about how changes in the brain contribute to changes in wellbeing.

Night-time blood pressure assessment is found to be important in diagnosing hypertension

Around 15% of people aged 40-75 may have a form of undiagnosed high blood pressure (hypertension) that occurs only at night-time. Because they do not know about this, and therefore are not being treated for it, they are at a higher risk of cardiovascular disease such as stroke, heart failure, and even death, suggests new research from the University of Oxford published in the British Journal of General Practice.

Major new NIHR Global Health Research Unit to focus on data science and genomic surveillance of antimicrobial resistance

The Centre for Genomic Pathogen Surveillance, part of the Big Data Institute at the University of Oxford, has been awarded funding worth £7m for their work as an NIHR Global Health Research Unit (GHRU) for the next five years. The Centre’s research and capacity building work focuses on delivering genomics and enabling data for the surveillance of antimicrobial resistance (AMR).

How artificial intelligence is shaping medical imaging

Dr Qiang Zhang of the Radcliffe Department of Medicine explains how artificial intelligence is being used to help researchers and physicians interpret medical imaging.

Researchers describe how cancer cells can defend themselves from the consequences of certain genetic defects

Researchers in Department of Physiology, Anatomy and Genetics have identified a rescue mechanism that allows cancers to overcome the consequences of inactivating mutations in critically important genes.